Research scientists like Silviu and team tend to be optimists.
In such a cut-throat brutal world, that can be a disadvantage.
Nice guys finish last look at Cephalon.
You wonder what risks we have incurred by letting Novartis look under the hood, but SI and team aren't that naive.
I think it was bad timing as others point out re Covid19 etc and the horrific impact of Trump-originated corruption and implications with the FDA and conflict of interest.
The FDA is still sorting itself out. Even though much of it is old news, it's still salient. IMO.
banter and General Discussion, page-8616
-
- There are more pages in this discussion • 2,441 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.025(2.29%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.321M | 3.008M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 25940 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6627 | 18 |
View Market Depth
| Last trade - 15.34pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |